Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC)

Supportive Care in Cancer

Volumn 23, Issue 11, 2015, Pages 3281-3288

  Rapoport, Bernardo ^a   Chua, Daniel ^b   Poma, Allen ^c   Arora, Sujata ^c   Wang, Yan ^c   Fein, Luis Enrique ^d  

^a Medical Oncology Centre of Rosebank   (South Africa)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

^c TESARO   (United States)

^d Centro Oncologico de Rosario   (Argentina)

Author keywords

Antiemetic; Chemotherapy induced nausea and vomiting (CINV); NK 1 receptor antagonist; Rolapitant

Indexed keywords

CISPLATIN; DEXAMETHASONE; ONDANSETRON; PLACEBO; ROLAPITANT; 8-((1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY)METHYL)-8-PHENYL-1,7-DIAZASPIRO(4,5)DECAN-2-ONE; ANTINEOPLASTIC AGENT; NEUROKININ 1 RECEPTOR ANTAGONIST; SPIRO COMPOUND;

ABDOMINAL PAIN; ADULT; AGED; ANOREXIA; ARTICLE; ATTENTION DISTURBANCE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; CONVULSION; DEHYDRATION; DISEASE CONTROL; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEADACHE; HIGHLY EMETOGENIC CHEMOTHERAPY; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; TREATMENT RESPONSE; VOMITING; CHEMICALLY INDUCED; CLINICAL TRIAL; INDUCTION CHEMOTHERAPY; MIDDLE AGED; NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; DEXAMETHASONE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUROKININ-1 RECEPTOR ANTAGONISTS; ONDANSETRON; SPIRO COMPOUNDS; VOMITING; YOUNG ADULT;

EID: 84942505515     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-015-2738-1     Document Type: Article

References (36)

1. Aapro M, Molassiotis A, Dicato M, Peláez I, Rodríguez-Lescure Á, Pastorelli D, Ma L, Burke T, Gu A, Gascon P, Roila F, PEER investigators (2012) The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann Oncol 23:1986–1992
2. Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, Morrow G, Rao KV, Schwartz RN, Lyman GH, American Society of Clinical Oncology (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29:4189–4198
3. Schwartzberg LS, Grunberg SM, Kris MG (2011) Recent advances and updated guidelines in the management of chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 9(11 Suppl 27):1–14
4. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, De Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100:2261–2268
5. Warr JK (2014) Prognostic factors for chemotherapy induced nausea and vomiting. Eur J Pharmacol 722:192–196
6. Molassiotis A, Aapro M, Dicato M, Gascon P, Novoa SA, Isambert N, Burke TA, Gu A, Roila F (2014) Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 47:839–848
7. Neymark N, Crott R (2005) Impact of emesis on clinical and economic outcomes of cancer therapy with highly emetogenic chemotherapy regimens: a retrospective analysis of three clinical trials. Support Care Cancer 13:812–818
8. Van Laar ES, Desai JM, Jatoi A (2015) Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2,388 health care providers. Support Care Cancer 23:151–157
9. Rojas C, Raje M, Tsukamoto T, Slusher BS (2014) Molecular mechanisms of 5-HT (3) and NK (1) receptor antagonists in prevention of emesis. Eur J Pharmacol 722:26–37
10. Feyer P, Jordan K (2011) Update and new trends in antiemetic therapy: the continuing need for novel therapies. Ann Oncol 22:30–38
11. NCCN (2011) NCCN clinical practice guidelines in oncology: antiemesis version 1.2012. Fort Washington, PA
12. Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:232–243
13. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobieranda F (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822–2830
14. Rojas C, Slusher BS (2012) Pharmacological mechanism of 5-HT3 and tachykinin NK-1 receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol 684:1–7
15. Morrow GR, Navari RM, Rugo HS (2014) Clinical roundtable monograph: new data in emerging treatment options for chemotherapy-induced nausea and vomiting. Clin Adv Hematol Oncol 12(3 Suppl 9):1–142
16. Navari RM (2013) Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents. Drugs 73:249–262
17. Akynzeo Product Information (2014) Eisai Inc., Woodcliff Lakes, New Jersey
18. Emend Package Insert (2012) Merck & Co. Inc., Whitehouse Station, New Jersey
19. Poma A, Christensen J, Pentikis H, Arora S, Hedley HL (2013) Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate. Poster 3441 presented at the MASCC International Symposium, Berlin, Germany, June 27–29
20. Poma A, Christensen J, Davis J, Kansra V, Martell RE, Hedley ML (2014) Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist. J Clin Oncol 32(suppl):e20690
21. Lindley CM, Hirsch JD, O’Neill CV, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340
22. Gralla RJ, Bosnjak SM, Hontsa A, Balser C, Rizzi G, Rossi G, Borroni ME, Jordan K (2014) A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy. Ann Oncol 25:1333–1339
23. Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ (2006) Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14:354–360
24. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ, Aprepitant Protocol 052 Study Group (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112–4119
25. Saito H, Yoshizawa H, Yoshimori K, Katakami N, Katsumata N, Kawahara M, Eguchi K (2013) Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol 24:1067–1073
26. Aapro MS, Grunberg SM, Manikhas GM, Olivares G, Suarez T, Tjulandin SA, Bertoli LF, Yunus F, Morrica B, Lordick F, Macciocchi A (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17:1441–1449
27. Aapro M, Rugo H, Rossi G, Rizzi G, Borroni ME, Bondarenko I, Sarosiek T, Oprean C, Cardona-Huerta S, Lorusso V, Karthaus M, Schwartzberg L, Grunberg S (2014) A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 25:1328–1333
28. Aapro MS, Walko CM (2010) Aprepitant: drug-drug interactions in perspective. Ann Oncol 21:2316–2323
29. Celio L, Ricchini F, De Braud F (2013) Safety, efficacy, and patient acceptability of single-dose fosaprepitant regimen for the prevention of chemotherapy-induced nausea and vomiting. Patient Prefer Adherence 7:391–400
30. Hegerova LT, Leal AD, Grendahl DC, Seisler DK, Sorgatz KM, Anderson KJ, Hilger CR, Loprinzi CL (2015) An analysis of fosaprepitant-induced venous toxicity in patients receiving highly emetogenic chemotherapy. Support Care Cancer 23:55–59
31. Lundberg JD, Crawford BS, Phillips G, Berger MJ, Wesolowski R (2014) Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. Support Care Cancer 22:1461–1466
32. Hesketh PJ, Rossi G, Rizzi G, Palmas M, Alyasova A, Bondarenko I, Lisyanskaya A, Gralla RJ (2014) Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study. Ann Oncol 25:1340–1346
33. Colon-Gonzalez F, Kraft WK (2010) Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert Opin Drug Metab Toxicol 6:1277–1286
34. 1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone. Support Care Cancer 21:2783–2791
35. Rapoport BL, Chasen M, Poma A, Hedley ML, Martell RE, Navan RM (2014) Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving cisplatin-based, highly emetogenic chemotherapy (MEC). Poster presented at the American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, May 30-June 1
36. Schnadig ID, Modiano MR, Poma A, Hedley ML, Martell RE, Schwartzberg LS (2014) Rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC). Poster presented at the American Society of Clinical Oncology Annual Meeting, Chicago, Illinois, May 30-June 1